Indication
for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer -in combination with fulvestrant in women who have received prior endocrine therapy

Medicine details

Medicine name:
palbociclib (Ibrance)
SMC ID:
SMC2149
Pharmaceutical company
Pfizer Ltd
BNF chapter
Submission type
Full submission
Status
Advice due date:
Q3 2019
SMC meeting date:
Q2 2019
Patient group submission deadline:
01 April 2019